StockNews.com started coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Get Free Report) in a note issued to investors on Monday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Separately, Maxim Group reiterated a “hold” rating on shares of Agile Therapeutics in a research note on Monday, March 18th.
Get Our Latest Stock Analysis on AGRX
Agile Therapeutics Trading Down 0.4 %
Agile Therapeutics (NASDAQ:AGRX – Get Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($0.63) earnings per share for the quarter. The firm had revenue of $5.72 million during the quarter.
Hedge Funds Weigh In On Agile Therapeutics
A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC increased its position in Agile Therapeutics, Inc. (NASDAQ:AGRX – Free Report) by 10.2% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after purchasing an additional 10,000 shares during the quarter. Armistice Capital LLC owned approximately 3.65% of Agile Therapeutics worth $211,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 10.92% of the company’s stock.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Read More
- Five stocks we like better than Agile Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- RXO Shares Surge Following New Acquisition Deal
- What Investors Need to Know About Upcoming IPOs
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Pros And Cons Of Monthly Dividend Stocks
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.